Check out what we’ve been up to and where we can connect!
April 24, 2021
Results of the Adaptive COVID-19 Treatment Trial (ACTT)-2 investigating combination treatment with baricitinib, a Janus kinase inhibitor, and remdesivir for the treatment of COVID-19 in hospitalized adults were published in the New England Journal of Medicine (NEJM) on March 4, 2021, showing that the combination treatment was superior to remdesivir alone.
March 29, 2021
Phase I/II studies to evaluate human placental hematopoietic stem cell–derived natural killer (NK) cell therapy to treat COVID-19 in hospitalized adults are currently ongoing as part of our partnership with the Infectious Disease Research Institute (IDRI).
February 8, 2021
In a recent podcast discussion with TrialSite News, Claudia Christian, Senior Vice President, Clinical Operations at FHI Clinical, shares how the company’s experience in complex clinical research in resource-limited settings helps to ensure health equity and get life-saving vaccines to those who need them most.
November 20, 2020
The U.S. FDA granted emergency use authorization (EUA) for the use of baricitinib in combination with remdesivir to treat COVID-19 in hospitalized adults and children at least two years of age requiring supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation.
March 17-19, 2022
At the 5th annual WAC-CREP conference, FHI Clinical employees are presenting findings from research being conducted within the Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL) network.
February 22, 2022
Join us for this plenary discussion in which experts in infectious diseases discuss how real-world epidemiology data, site capacity data and biosurveillance methodology could help identify TB-prevalent populations during protocol design, helping to ensure an adequate sample for TB vaccine development.
February 22-25, 2022
Attending the Global Forum on TB Vaccines? Visit our booth to learn more about our services or schedule a meeting with our team.
February 7-10, 2022
Attending SCOPE? Learn more about how we ensure best-fit sites with the most appropriate capabilities and patient populations tailored to your study protocol. Contact us to set aside time to review your feasibility and study start-up needs.
November 30 – December 2, 2021
Attending the World Vaccine and Immunotherapy Congress West Coast? Schedule a meeting with an FHI Clinical team member who will be in attendance at the event.
November 17-21, 2021
Attending the ASTMH 2021 Annual Meeting? Schedule a meeting with an FHI Clinical team member who will be in attendance at the event or stop by one of our poster presentations.
U.S.A (Headquarters)
359 Blackwell Street, Suite 200, Durham, NC 27701 USA
South Africa
121 Amkor Road, Lyttelton Manor, Centurion, 0157, SOUTH AFRICA
Kenya
Britam Towers, 24th Floor, Hospital Road, Upper Hill KENYA
Liberia
The Cape Hotel, Mamba Point, Monrovia LIBERIA